{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T16:17:14Z","timestamp":1788797834681,"version":"build-2803163510"},"reference-count":19,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2015,6,8]],"date-time":"2015-06-08T00:00:00Z","timestamp":1433721600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Cardiology"],"published-print":{"date-parts":[[2015,8]]},"abstract":"<jats:title><jats:styled-content style=\"fixed-case\">ABSTRACT<\/jats:styled-content><\/jats:title><jats:sec><jats:title><jats:italic>Background<\/jats:italic><\/jats:title><jats:p>Ranolazine, a piperazine derivative with anti\u2010ischemic effects, reduces the frequency of angina and improves exercise performance in patients with chronic angina. The effects of ranolazine in patients with established ischemic heart disease and chronic angina undergoing percutaneous coronary intervention (<jats:styled-content style=\"fixed-case\">PCI<\/jats:styled-content>) for acute coronary syndromes (<jats:styled-content style=\"fixed-case\">ACS<\/jats:styled-content>) is not well described. We hypothesized that ranolazine would reduce ischemic events, regardless of revascularization.<\/jats:p><\/jats:sec><jats:sec><jats:title><jats:italic>Methods<\/jats:italic><\/jats:title><jats:p>We examined the 1\u2010year incidence of recurrent cardiovascular (<jats:styled-content style=\"fixed-case\">CV<\/jats:styled-content>) events in the subgroup of patients with prior chronic angina (n\u2009=\u20093565) enrolled in the randomized, double\u2010blind, placebo\u2010controlled Metabolic Efficiency with Ranolazine for Less Ischemia in Non\u2010<jats:styled-content style=\"fixed-case\">ST<\/jats:styled-content>\u2010Elevation <jats:styled-content style=\"fixed-case\">ACS<\/jats:styled-content> (<jats:styled-content style=\"fixed-case\">MERLIN<\/jats:styled-content>)\u2013Thrombolysis In Myocardial Infarction (<jats:styled-content style=\"fixed-case\">TIMI<\/jats:styled-content>) 36 trial who did or did not have a <jats:styled-content style=\"fixed-case\">PCI<\/jats:styled-content> within 30 days of the index event.<\/jats:p><\/jats:sec><jats:sec><jats:title><jats:italic>Results<\/jats:italic><\/jats:title><jats:p>Ranolazine reduced the risk of recurrent ischemia following admission regardless of whether patients had (hazard ratio [<jats:styled-content style=\"fixed-case\">HR<\/jats:styled-content>], 0.69; 95% confidence interval [<jats:styled-content style=\"fixed-case\">CI<\/jats:styled-content>] 0.51\u20100.92] or did not have <jats:styled-content style=\"fixed-case\">PCI<\/jats:styled-content> (<jats:styled-content style=\"fixed-case\">HR<\/jats:styled-content>, 0.81; 95% <jats:styled-content style=\"fixed-case\">CI<\/jats:styled-content>, 0.66\u20100.99; <jats:italic>P<\/jats:italic> interaction\u2009=\u20090.39). <jats:styled-content style=\"fixed-case\">CV<\/jats:styled-content> death, myocardial infarction, and recurrent ischemia were similarly lower with ranolazine in the <jats:styled-content style=\"fixed-case\">PCI<\/jats:styled-content> group (<jats:styled-content style=\"fixed-case\">HR<\/jats:styled-content>, 0.71; 95% <jats:styled-content style=\"fixed-case\">CI<\/jats:styled-content>, 0.55\u20100.91) vs the non\u2010<jats:styled-content style=\"fixed-case\">PCI<\/jats:styled-content> group (<jats:styled-content style=\"fixed-case\">HR<\/jats:styled-content>, 0.91; 95% <jats:styled-content style=\"fixed-case\">CI<\/jats:styled-content>, 0.78\u20101.06; <jats:italic>P<\/jats:italic> interaction\u2009=\u20090.10), with a nominally significant decrease in <jats:styled-content style=\"fixed-case\">CV<\/jats:styled-content> death (<jats:styled-content style=\"fixed-case\">HR<\/jats:styled-content>, 0.39; 95% <jats:styled-content style=\"fixed-case\">CI<\/jats:styled-content>, 0.16\u20100.93) in the <jats:styled-content style=\"fixed-case\">PCI<\/jats:styled-content> group vs no difference in the non\u2010<jats:styled-content style=\"fixed-case\">PCI<\/jats:styled-content> group (<jats:styled-content style=\"fixed-case\">HR<\/jats:styled-content>, 1.19; 95% <jats:styled-content style=\"fixed-case\">CI<\/jats:styled-content>, 0.89\u20101.59; <jats:italic>P<\/jats:italic> interaction\u2009=\u20090.02).<\/jats:p><\/jats:sec><jats:sec><jats:title><jats:italic>Conclusions<\/jats:italic><\/jats:title><jats:p>In patients with chronic angina, ranolazine reduced recurrent ischemic events, regardless of whether patients did or did not receive <jats:styled-content style=\"fixed-case\">PCI<\/jats:styled-content> within 30 days of a non\u2010<jats:styled-content style=\"fixed-case\">ST<\/jats:styled-content>\u2010segment <jats:styled-content style=\"fixed-case\">ACS<\/jats:styled-content>.<\/jats:p><\/jats:sec>","DOI":"10.1002\/clc.22425","type":"journal-article","created":{"date-parts":[[2015,6,11]],"date-time":"2015-06-11T05:40:56Z","timestamp":1434001256000},"page":"469-475","source":"Crossref","is-referenced-by-count":30,"title":["Effects of Ranolazine in Patients With Chronic Angina in Patients With and Without Percutaneous Coronary Intervention for Acute Coronary Syndrome: Observations From the <scp>MERLIN\u2010TIMI<\/scp> 36 Trial"],"prefix":"10.1002","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8977-2821","authenticated-orcid":false,"given":"Jorge A.","family":"Gutierrez","sequence":"first","affiliation":[{"name":"TIMI Study Group, Cardiovascular Division, Department of Medicine Brigham and Women's Hospital, and Harvard Medical School  Boston Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ewa","family":"Karwatowska\u2010Prokopczuk","sequence":"additional","affiliation":[{"name":"Gilead Science, Inc.  Foster City California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabina A.","family":"Murphy","sequence":"additional","affiliation":[{"name":"TIMI Study Group, Cardiovascular Division, Department of Medicine Brigham and Women's Hospital, and Harvard Medical School  Boston Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luiz","family":"Belardinelli","sequence":"additional","affiliation":[{"name":"Gilead Science, Inc.  Foster City California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramin","family":"Farzaneh\u2010Far","sequence":"additional","affiliation":[{"name":"Gilead Science, Inc.  Foster City California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gennyne","family":"Walker","sequence":"additional","affiliation":[{"name":"Gilead Science, Inc.  Foster City California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Morrow","sequence":"additional","affiliation":[{"name":"TIMI Study Group, Cardiovascular Division, Department of Medicine Brigham and Women's Hospital, and Harvard Medical School  Boston Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin M.","family":"Scirica","sequence":"additional","affiliation":[{"name":"TIMI Study Group, Cardiovascular Division, Department of Medicine Brigham and Women's Hospital, and Harvard Medical School  Boston Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2015,6,8]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0b013e31828124ad"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.2147\/VHRM.S11100"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2013.01.014"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.105.597500"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2003.11.045"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2009.01.037"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.291.3.309"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2006.05.044"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.297.16.1775"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2006.01.004"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2006.01.099"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2008.07.006"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000139333.83620.5D"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.RES.84.12.1469"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.RES.84.12.1401"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1152\/ajpheart.00855.2006"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/0735-1097(93)90743-K"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.ph.54.030192.001331"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2013.08.004"}],"container-title":["Clinical Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fclc.22425","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/clc.22425","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T16:13:25Z","timestamp":1696349605000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/clc.22425"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6,8]]},"references-count":19,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2015,8]]}},"alternative-id":["10.1002\/clc.22425"],"URL":"https:\/\/doi.org\/10.1002\/clc.22425","archive":["Portico"],"relation":{},"ISSN":["0160-9289","1932-8737"],"issn-type":[{"value":"0160-9289","type":"print"},{"value":"1932-8737","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,6,8]]}}}